The Role of 18F-FDG PET/CT in Evaluating Elevated Levels of Tumor Markers in Breast Cancer

Journal Title: Molecular Imaging and Radionuclide Therapy - Year 2018, Vol 27, Issue 1

Abstract

Objective: Our aim was to assess the diagnostic performance of integrated positron emission tomography/computed tomography (PET/CT) in the follow-up of breast cancer patients, who underwent a PET/CT scan due to a suspicion of recurrence based on elevated levels of serum tumor markers. Methods: Seventy-seven consecutive patients were included in this study. PET/CT scan results were compared with the final diagnoses that were obtained from histopathological sampling or a minimum 6 months of radiological follow-up. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and the diagnostic accuracy of PET/CT for detecting recurrence were calculated. Results: All 77 patients had increased serum cancer antigen 15-3 levels while 37 had increased serum carcinoembryonic antigen levels. According to PET/CT scan results, 59 of 77 patients (PET/CT positive) had local recurrence and/or distant metastasis while there was no pathological finding in 18 patients (PET/CT negative). In a follow-up of minimum 6 months, tumor recurrence was confirmed in 58 of “PET/CT positive” patients while no tumor recurrence was detected in 16 of “PET/CT negative” patients. According to these results the sensitivity, specificity, PPV, NPV and the diagnostic accuracy of PET/CT for detecting recurrence on a per-person basis were calculated as 98%, 88%, 96%, 94% and 96%, respectively. Conclusion: In case of elevated levels of serum tumor markers, PET/CT has a high diagnostic accuracy in detecting tumor recurrence in patients with breast cancer, and it is an effective modality that can be used in addition to conventional imaging techniques.

Authors and Affiliations

İnan Göktaş, Hakan Cayvarlı

Keywords

Related Articles

Efficacy of 18F-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography/Computerized Tomography for Bone Marrow Infiltration Assessment in the Initial Staging of Lymphoma

Objective: Currently 18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography/computerized tomography (PET/CT) is being successfully used for staging and follow-up of Hodgkin’s lymphoma (HL) and non-Hodgkin’...

Striking Visualization of Diffuse Congenital Nesidioblastosis on Ga-68 DOTATATE PET/CT

“Nesidioblastosis”, later renamed as “persistent hyperinsulinemic hypoglycemia of infancy” presents as either focal or diffuse neo-differentiation of pancreatic Langerhans islet cells from the ductal epithelium. Differen...

Incidental “Urinoma” in 18F-FDG PET/CT Scan

18F-FDG PET/CT scanning was performed for the primary staging of a 47-year-old man with urothelial carcinoma. The patient underwent biopsy by ureteroscopy 15 days ago and the PET images revealed 18F-FDG accumulation in t...

A Diagnostic Challenge: Erdheim Chester Disorder

Erdheim-Chester disease (ECD) is a rare, multisystemic, idiopathic disease often associated with BRAF V600E mutation. Its diagnosis is typically delayed and challenging due to its variable manifestations. Although it has...

Download PDF file
  • EP ID EP258107
  • DOI 10.4274/mirt.74436
  • Views 108
  • Downloads 0

How To Cite

İnan Göktaş, Hakan Cayvarlı (2018). The Role of 18F-FDG PET/CT in Evaluating Elevated Levels of Tumor Markers in Breast Cancer. Molecular Imaging and Radionuclide Therapy, 27(1), 3-9. https://europub.co.uk/articles/-A-258107